These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1688048)

  • 1. Effects of a beta 3-adrenoceptor agonist, BRL 26830A, on insulin and glucagon release in mice.
    Yoshida T; Hiraoka N; Kondo M
    Endocrinol Jpn; 1991 Dec; 38(6):641-6. PubMed ID: 1688048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin.
    Yoshida T
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):237S-241S. PubMed ID: 1345886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice.
    Yoshida T; Hiraoka N; Yoshioka K; Hasegawa G; Kondo M
    Endocrinol Jpn; 1991 Aug; 38(4):397-403. PubMed ID: 1687027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
    Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P
    Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT; Rennie MJ
    Int J Obes Relat Metab Disord; 1992 Sep; 16(9):685-94. PubMed ID: 1356939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigation of obesity by BRL 26830A, a new beta-adrenoceptor agonist, in MSG obese mice.
    Yoshida T; Yoshioka K; Kamanaru K; Hiraoka N; Kondo M
    J Nutr Sci Vitaminol (Tokyo); 1990 Feb; 36(1):75-80. PubMed ID: 1972962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
    Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P
    Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate supply for thermogenesis induced by the beta-adrenoceptor agonist BRL 26830A.
    Wilson S; Thurlby PL; Arch JR
    Can J Physiol Pharmacol; 1987 Feb; 65(2):113-9. PubMed ID: 2882828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.
    Arch JR; Ainsworth AT
    Am J Clin Nutr; 1983 Oct; 38(4):549-58. PubMed ID: 6137948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist.
    Connacher AA; Jung RT; Mitchell PE
    Br Med J (Clin Res Ed); 1988 Apr; 296(6631):1217-20. PubMed ID: 2898268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the beta 3-adrenoceptor agonist BRL 37344 on lipomobilization and plasma glucose levels in conscious fasted rabbits.
    Reverte M; Rivas-Cabañero L
    Can J Physiol Pharmacol; 1996 Mar; 74(3):251-6. PubMed ID: 8773403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice.
    Bryson JM; Wensley VR; Phuyal JL; Caterson ID; Cooney GJ
    Horm Metab Res; 1999 May; 31(5):317-22. PubMed ID: 10422727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alpha 2- and beta-adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin-induced diabetic rats.
    Hirose H; Maruyama H; Ito K; Kido K; Koyama K; Saruta T
    Metabolism; 1993 Aug; 42(8):1072-6. PubMed ID: 8102194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats.
    Sennitt MV; Arch JR; Levy AL; Simson DL; Smith SA; Cawthorne MA
    Biochem Pharmacol; 1985 Apr; 34(8):1279-85. PubMed ID: 2859857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies with the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):258S-261S. PubMed ID: 1345890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.
    Liu YL; Cawthorne MA; Stock MJ
    Br J Pharmacol; 1996 Mar; 117(6):1355-61. PubMed ID: 8882636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.
    Carroll MJ; Lister CA; Sennitt MV; Stewart-Long N; Cawthorne MA
    Diabetes; 1985 Nov; 34(11):1198-204. PubMed ID: 2864298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose transporter in insulin sensitive tissues of lean and obese mice. Effect of the thermogenic agent BRL 26830A.
    Le Marchand-Brustel Y; Olichon-Berthe C; Grémeaux T; Tanti JF; Rochet N; Van Obberghen E
    Endocrinology; 1990 Dec; 127(6):2687-95. PubMed ID: 2249621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β3-adrenoceptor-mediated increased circulating transaminase levels in mice treated with its agonist BRL 37344.
    Kasahara H; Muto S; Motokawa Y; Arisaka N; Kobayashi S; Souma S; Kuroda J
    J Toxicol Sci; 2010 Oct; 35(5):779-84. PubMed ID: 20930473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat.
    Bahl AK; Clayton NM; Coates J; Martin DP; Oakley IG; Strong P; Trevethick MA
    Br J Pharmacol; 1996 Feb; 117(3):580-586. PubMed ID: 8821552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.